was clearly observed between 4 and 12 h of treatment ( Figure  1c) . Thus, the increase in the level of ROS anticipated the onset of apoptosis triggered by MG132. Interestingly, it has been shown that ROS induce oxidation of intracellular proteins, and that proteasome is involved in the removal of oxidized proteins. 14 These findings suggested that treatment with MG132 can lead to an accumulation of these proteins and in particular protein-bound carbonyl groups, which are suitable markers for protein oxidation. 15 In agreement with these considerations we demonstrated, using an ELISA kit (Zentech Technologies), that carbonyl proteins increased from 0.2570.02 to 0.4870.05 pmol/mg of protein after treatment for 48 h with 1.0 mM MG132. Our results also showed that oxidants were responsible for the apoptotic effect exerted by MG132, since the addition of antioxidants, such as GSH, N-acetylcysteine (NAC) or catalase prevented the generation of ROS (not shown), and at the same time, markedly reduced the cytotoxic effect induced by MG132 (Figure 1d ). Moreover, treatment with MG132 caused depolarization of the mitochondrial transmembrane potential (Dc m ) (Figure 1e ) with the consequent release of cytochrome c from mitochondria to cytosol (Figure 1f) . It is well known that efflux of cytochrome c in the cytosol causes the activation of caspases, 16 the cysteine proteases required for the execution of the cell death program. By Western blotting it is shown that in Saos-2 cells, MG132 induced fragmentation of procaspase-3 and production of the active form of caspase-3 as well as the breakdown of PARP, a specific substrate of caspase-3 ( Figure 1f ). However, MG132 treatment was unable to induce fragmentation of procaspase-8 (not shown). Caspase-3 plays a crucial role in MG132-induced apoptosis, as suggested by the finding that 100 mM z-VAD, a cell-permeable, broad spectrum inhibitor of caspase activity, protected the cells from the loss of viability induced by MG132 (Figure 1a) . At the same time, it suppressed the activation of caspase-3 as well as the consequent degradation of PARP (Figure 1f ) and the morphological changes because of apoptosis (not shown). As z-VAD did not prevent the loss of Dc m induced by MG132, we suggest that the involvement of mitochondria preceded caspase-3 activation in MG132-induced apoptosis. In addition, our results provide evidence that 10 mM NAC prevented the effects of MG132 on the loss of Dc m , as well as on the translocation of cytochrome c and the activation of caspase-3 (not shown). These findings suggest that all these effects may be a consequence of the increased generation of ROS caused by MG132. Therefore, they can be considered intermediate steps in the MG132-induced pathway leading to apoptosis.
The proteins of the Bcl-2 family are essential factors in the control of apoptosis. 17 In Saos-2 cells, treatment with MG132 provoked only a modest decrease in the levels of the two antiapoptotic factors Bcl-2 and Bcl-X L . Apart from Bcl-X L (31 kDa), Bcl-X gene has been shown to generate another isoform, called Bcl-X S (21 kDa), 18 which can induce translocation of cytochrome c and the consequent activation of caspase-3. As shown in Figure 1f , Bcl-X S was not visible in untreated Saos-2 cells, but appeared after treatment with MG132. It is possible that these changes in the expression of Bcl-X isoforms contributed to the release of cytochrome c from mitochondria. On the other hand, no variations of Bax 5% SDS-PAGE to analyze pRb or in 10% in the other cases, then blotted and detected using specific antibodies. Equal loading of proteins was checked by red S Ponceau staining (data not shown)
were observed in Saos-2 cells under treatment with MG132 (not shown). Human osteosarcoma Saos-2 cells lack p53 and contain a nonfunctional form of pRb (p95).
19 p53 and the retinoblastoma protein (pRb) are products of tumor-suppressor genes, which are fundamental in the control of cell proliferation. During cell cycle, pRb behaves as a transcriptional repressor by sequestering members of the E2F family, required for the progression of cells from G1 into S phase. 20 pRb is also involved in the terminal differentiation of many cells behaving as a transcriptional coactivator by binding to and potentiating the activity of tissue-specific transcription factors. 21 Finally, pRb has been reported to exert a protective function against apoptosis in differentiating cells, but the mechanism of its action is not clearly defined. 22 Differently, p53 acts as a transcription factor and induces apoptotic activity by regulating a set of genes. 23 To test the effect exerted by pRb or p53 expression on the apoptosis induced by proteasome inhibitors, we obtained stable clones of RB-or p53-reconstituted cells by introducing cDNA vectors endowed with the wild type forms of RB or p53 genes (Figure 1f ). Compared to parental cells, all the sublines expressing pRb showed a slower rate of cell growth. Under light microscopy, most of the cells appeared enlarged and flattened, with many dendritic-like protrusions resembling differentiative features. The introduction of RB gene into Saos-2 cells prevented the cells from the effects of 1.0 mM MG132, such as the increase in ROS, the dissipation of Dc m and the activation of caspase-3 (not shown). As a consequence, treatment of RB-transfected (RBT) cells with 1.0 mM MG132 determined only a modest cytotoxic effect, which appeared after a prolonged lag phase (Figure 1a ). An interesting observation was that the intensity of the band corresponding to Bcl-2 was much higher in RBT cells than in parental cells (Figure 1f) . However, since Bcl-2 has been reported to counteract the production of ROS and protect the cells from damages caused by oxidative stress, 24 the increase in Bcl-2 level might be responsible for the reduced cytotoxic effect of MG132 in RBT cells. Clones of p53-reconstituted (p53T) cells showed a susceptibility to MG132-induced apoptosis, which was higher than that shown by parental cells (Figure 1a ). This fact was most likely correlated either with an increase in p53 level resulting from the inhibition of proteasome by MG132 or with the decrease in Bcl-2 and Bcl-X L levels, which was higher in p53T cells than in parental cells (Figure 1f ).
Our results demonstrate that the introduction of RB gene into Saos-2 cells exerts a protective influence against apoptosis, while the introduction of p53 potentiates the apoptotic effect induced by MG132. These findings suggest that the efficacy of treating osteosarcomas with proteasome inhibitors may vary in relation to the alterations in RB or p53 genes presented in tumor cells.
